Novo to supply drugs to Greece, faces fines; AZ deemed likely to prevail on Crestor patent;

> Novo Nordisk (NOVOb.CO) will supply Greece with its drugs as normal after authorities proposed a new pricing formula, but could face fines for pulling them off the market, Greece's drug watchdog said. Report

> Barclays raised its rating on AstraZeneca (UK:AZN, AZN) to overweight, saying it believes the company stands a 60 percent to 65 percent chance of victory in the U.S. patent dispute around cholesterol treatment Crestor. Report

> Generic companies hoping to market a cheap copy of GlaxoSmithKline's (GSK.L) best-selling inhaled lung drug Advair might have wait until 2012 before winning a green light from regulators in Europe. Report

> Only 38 percent of European biopharmaceutical companies feel that they have the ability to influence market access stakeholders, according to new research. Report

> GlaxoSmithKline received a second rebuff in as many days from Britain's NICE when the healthcare cost watchdog ruled its platelet-boosting drug Revolade was not worth using on the state health service. Report

> Harbin Pharmaceutical (HPG), the Chinese buyer of Pfizer's swine vaccine unit, is preparing workshops and technicians to take over the production line, the company announced. Report

> A drug commonly used to treat gout may help patients with chronic kidney disease keep their condition in check and reduce the risk of heart problems, Spanish scientists said. Report

> Hospira said that European Union regulators have approved its drug Nivestim as a treatment for certain side effects of chemotherapy. Report

Biotech News

 @FierceBiotech: Covance plans 300 hires for Indiana campus. Report | Follow @FierceBiotech

 @JohnCFierce: Sharing data on failed Alzheimer's trials makes a lot of sense. It's also cool to see biopharma companies working together. | Follow @JohnCFierce

> Big Pharma coalition will pool data on failed Alzheimer's drugs. Report

> Precision Therapeutics gets $33M to support ChemoFx. Story

> UCB ups stake in oncology partner. Item

> BMS, Pfizer wrap apixaban stroke trial early on positive verdict. Results

> Inotek gathers $18M as it plots PhII trials. News

> FDA panel hands Novartis lopsided endorsement of oral MS therapy. Article

And Finally... Why aren't more patients getting the shingles vaccine? Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.